<DOC>
	<DOCNO>NCT00926757</DOCNO>
	<brief_summary>Hepatitis B ( HBV ) reactivation hepatitis flare induce cytotoxic chemotherapy common cancer patient chronic HBV infection . Lymphoma patient previous infected HBV negative HBsAg risk HBV reactivation chemotherapy , prophylactic antiviral treatment routine current American Association Study Liver Diseases ( AASLD ) guideline . Prophylactic entecavir might reduce risk HBV reactivation patient .</brief_summary>
	<brief_title>Prophylactic Use Entecavir Non-Hodgkin 's Lymphoma Patients With Resolved Hepatitis B</brief_title>
	<detailed_description>Hepatitis B ( HBV ) reactivation hepatitis flare induce cytotoxic chemotherapy common cancer patient chronic HBV infection . It best characterized patient hematological malignancy non-Hodgkin 's lymphoma also occur patient solid tumor . Reactivation initiation chemotherapy may cause delay cancer treatment decrease overall survival . The direct mortality cause HBV reactivation , predominantly acute liver failure , range 4 % 60 % . Based currently available information , well document HBV carrier receive antiviral agent prevent hepatitis B flare receive immunosuppressive agent chemotherapy . However , development hepatitis , acute liver failure , mortality occur among patient HBsAg negative anti-HBc positive time chemotherapy . Therefore , initiation cytotoxic chemotherapy case non-Hodgkin 's lymphoma , unknown whether patient previous infected HBV negative HBsAg routinely receive antiviral agent prevention HBV flare . In addition , major concern long-term lamivudine use selection drug-resistant mutation . Based , design current study address important issue . Eligible patient newly diagnose , histologically proven anti-CD20-positive non-Hodgkin 's lymphoma hospital . Patients negative HBsAg positive serum anti-HBc . After sign patient consent form , serum sample store genotyping quantitative HBV DNA test . Patients randomize two group . In prophylactic use group , participant initiate entecavir 0.5 mg/day orally day 1 first course chemotherapy . Entecavir treatment continue 3 month completion chemotherapy achieve remission hepatitis ( ALT normalization undetectable HBV DNA ) . In therapeutic use group , patient start entecavir therapy , 0.5 mg/day orally , elevation ALT ( &gt; 100 U/L ) HBV DNA ( &gt; 2000 IU/ml ) develop follow-up , situation HBsAg reverse seroconversion , continue entecavir treatment hepatitis resolve . The primary endpoint incidence HBV reactivation within 12 month complete chemotherapy diffuse large B cell follicular lymphoma patient receive R-CHOP regimen . The secondary endpoint incidence HBsAg reverse seroconversion within 12 month complete chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>CD20 positive lymphoma negative HBsAg positive antiHBc age 16 year old alanine aminotransferase less 2 time upper limit normal bilirubin &lt; 2.5 mg/dL neutrophil &gt; 2000/mm3 platelet &gt; 100,000/mm3 creatinine &lt; 1.5 mg/dL urea nitrogen &lt; 25 mg/dL Eastern Cooperative Oncology Group performance score 0 2 ChildPugh class B C cirrhosis grade 2 great heart failure NYHA classification previous chemotherapy , radiotherapy , concurrent glucocorticoid therapy reason primary liver disease , chronic hepatitis C , hepatitis D , autoimmune hepatitis , Wilsons ' disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>CD20</keyword>
	<keyword>Hepatitis B virus</keyword>
	<keyword>reactivation</keyword>
	<keyword>Rituximab</keyword>
</DOC>